Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
53results about How to "Thwart these maladies" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
InactiveUS6890763B2Maximize diversityThwart these maladiesAnalysis using chemical indicatorsPeptide/protein ingredientsDiseaseBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer.
Owner:NANOGEN INC
Biopolymer marker indicative of disease state having a molecular weight of 1424 daltons
InactiveUS20060024755A1Maximize diversityThwart these maladiesBiological testingBiopolymerSpectroscopy
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer.
Owner:JACKOWSKI GEORGE +5
IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Protein biopolymer markers predictive of insulin resistance
InactiveUS20060211138A1Thwart these maladiesApolipeptidesMaterial analysis by electric/magnetic meansDisease riskBiopolymer
Owner:JACKOWSKI GEORGE +1
Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance
InactiveUS20060211146A1Rapidly and accurately diagnosingConvenient treatmentProtease inhibitorsAnimals/human peptidesMass spectrometrySpectroscopy
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:JACKOWSKI GEORGE +1
Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
InactiveUS7314717B2Maximize diversityThwart these maladiesAnalysis using chemical indicatorsPeptide/protein ingredientsDiseaseBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer.
Owner:NANOGEN INC
Protein biopolymer markers predictive of insulin resistance
InactiveUS20060205091A1Thwart these maladiesApolipeptidesImmunoglobulins against animals/humansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:JACKOWSKI GEORGE +1
Betaine/GABA transport protein biopolymer marker indicative of insulin resistance
InactiveUS7132244B2Thwart these maladiesPeptide/protein ingredientsPeptide preparation methodsDisease riskBetaine
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Protein biopolymer markers indicative of insulin resistance
InactiveUS7135297B2Thwart these maladiesPeptide/protein ingredientsImmunoglobulins against animals/humansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against disease.
Owner:NANOGEN INC
Protein biopolymer markers predictive of insulin resistance
InactiveUS20060211140A1Thwart these maladiesApolipeptidesMaterial analysis by electric/magnetic meansDisease riskBiopolymer
Owner:JACKOWSKI GEORGE +1
Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance
InactiveUS20060211145A1Rapidly and accurately diagnosingConvenient treatmentPeptide preparation methodsDepsipeptidesDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:NANOGEN INC
Protein biopolymer markers indicative of insulin resistance
InactiveUS20060194339A1Thwart these maladiesPeptide/protein ingredientsImmunoglobulins against animals/humansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:NANOGEN INC
Protein biopolymer markers predictive of insulin resistance
InactiveUS7052849B2Rapidly and accurately diagnosingConvenient treatmentApolipeptidesImmunoglobulins against animals/humansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Protein biopolymer markers indicative of alzheimer's disease
InactiveUS7074576B2Thwart these maladiesNervous disorderPeptide/protein ingredientsDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Complement C3 precursor biopolymer markers predictive of type II diabetes
InactiveUS7097989B2Thwart these maladiesPeptide/protein ingredientsMaterial analysis by electric/magnetic meansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
InactiveUS7294688B2Maximize diversityThwart these maladiesPeptide/protein ingredientsImmunoglobulinsDiseaseBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer.
Owner:NANOGEN INC
Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
InactiveUS20060211048A1Maximize diversityThwart these maladiesBiological testingImmunoassaysBiopolymerSpectroscopy
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer.
Owner:JACKOWSKI GEORGE +4
Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance
InactiveUS20060134699A1Thwart these maladiesSerum immunoglobulinsImmunoglobulins against animals/humansBiopolymerTrypsin inhibitor
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:JACKOWSKI GEORGE +1
Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
InactiveUS7049397B2Maximize diversityThwart these maladiesPeptide/protein ingredientsImmunoglobulinsBiopolymerMass spectrometry
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer.
Owner:NANOGEN INC
Complement c3 precursor biopolymer markers predictive of type ii diabetes
InactiveUS20060160232A1Rapidly and accurately diagnosingConvenient treatmentPeptide/protein ingredientsMaterial analysis by electric/magnetic meansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:NANOGEN INC
Fibronectin biopolymer marker indicative of insulin resistance
InactiveUS7094549B2Thwart these maladiesImmunoglobulins against blood coagulation factorsPeptide/protein ingredientsDisease riskMedicine
Owner:NANOGEN INC +1
Ig heavy chain, ig kappa, ig lambda biopolymer markers predictive of alzheimers disease
InactiveUS20060160233A1Rapidly and accurately diagnosingConvenient treatmentCompound screeningApoptosis detectionDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:NANOGEN INC
Fibronectin precursor biopolymer markers indicative of alzheimer's disease
InactiveUS7179605B2Thwart these maladiesCompound screeningNervous disorderBiopolymerMass spectrometry
Owner:NANOGEN INC
Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons
InactiveUS6998243B2Maximize diversityThwart these maladiesPeptide/protein ingredientsPeptide sourcesBiopolymerMass spectrometry
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer.
Owner:NANOGEN INC
Glycoprotein and apolipoprotein biopolymer markers predictive of Alzheimers disease
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:NANOGEN INC
Method and kit for diagnosing myocardial infarction
InactiveUS7125726B2Maximize diversityThwart these maladiesPeptide/protein ingredientsPeptide sourcesBiopolymerSpectroscopy
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer.
Owner:ARTEMIS PROTEOMICS
Protein biopolymer markers predictive of type II diabetes
InactiveUS7125678B2Thwart these maladiesPeptide/protein ingredientsMaterial analysis by electric/magnetic meansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
HP biopolymer markers predictive of insulin resistance
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or the absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Biopolymer marker indicative of disease state having a molecular weight of 1525 daltons
InactiveUS20060024671A1Maximize diversityThwart these maladiesMicrobiological testing/measurementBiological testingBiopolymerSpectroscopy
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer.
Owner:ARTEMIS PROTEOMICS
Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons
InactiveUS7087435B2Maximize diversityThwart these maladiesPeptide/protein ingredientsPeptide sourcesDiseaseBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer.
Owner:NANOGEN INC
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com